EyePoint Pharmaceuticals Inc (EYPT)
16.16
-0.31
(-1.88%)
USD |
NASDAQ |
Apr 25, 16:00
16.16
0.00 (0.00%)
After-Hours: 20:00
EyePoint Pharmaceuticals Cash from Financing (TTM): 187.07M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 187.07M |
| September 30, 2023 | -31.47M |
| June 30, 2023 | -41.74M |
| March 31, 2023 | -5.361M |
| December 31, 2022 | -0.69M |
| September 30, 2022 | 107.88M |
| June 30, 2022 | 107.79M |
| March 31, 2022 | 107.68M |
| December 31, 2021 | 216.90M |
| September 30, 2021 | 118.87M |
| June 30, 2021 | 123.77M |
| March 31, 2021 | 125.82M |
| December 31, 2020 | 37.49M |
| September 30, 2020 | 28.96M |
| June 30, 2020 | 26.42M |
| March 31, 2020 | 42.68M |
| December 31, 2019 | 33.86M |
| September 30, 2019 | 60.78M |
| June 30, 2019 | 88.68M |
| March 31, 2019 | 94.12M |
| September 30, 2018 | 88.57M |
| June 30, 2018 | 60.67M |
| March 31, 2018 | 36.50M |
| December 31, 2017 | 15.54M |
| September 30, 2017 | 9.457M |
| Date | Value |
|---|---|
| June 30, 2017 | 8.503M |
| March 31, 2017 | 2.526M |
| December 31, 2016 | 16.66M |
| September 30, 2016 | 16.99M |
| June 30, 2016 | 16.99M |
| March 31, 2016 | 16.87M |
| December 31, 2015 | 0.338M |
| September 30, 2015 | 0.188M |
| June 30, 2015 | 0.235M |
| March 31, 2015 | 0.221M |
| December 31, 2014 | 7.678M |
| September 30, 2014 | 9.119M |
| June 30, 2014 | 19.04M |
| March 31, 2014 | 19.06M |
| December 31, 2013 | 11.60M |
| September 30, 2013 | 9.915M |
| June 30, 2013 | 4.669M |
| March 31, 2013 | 4.669M |
| December 31, 2012 | 4.669M |
| September 30, 2012 | 4.735M |
| June 30, 2012 | 0.114M |
| March 31, 2012 | 0.093M |
| December 31, 2011 | 10.17M |
| September 30, 2011 | 10.17M |
| June 30, 2011 | 10.06M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-41.74M
Minimum
Jun 2023
216.90M
Maximum
Dec 2021
70.28M
Average
60.78M
Median
Sep 2019
Cash from Financing (TTM) Benchmarks
| INVO Bioscience Inc | 7.392M |
| Bio-Path Holdings Inc | -- |
| Ocular Therapeutix Inc | 169.83M |
| Aileron Therapeutics Inc | 15.79M |
| Apellis Pharmaceuticals Inc | 394.50M |